HELLA Aktie

63,22EUR
-0,72EUR
-1,13%
18.01.2022

WKN: A13SX2 / ISIN: DE000A13SX22

  Kaufen  
Verkaufen
oder
Werbung

Times and Sales (XETRA)

ZeitKursUmsatz
Zur Zeit stehen keine Daten zur Verfügung
weiter
Werbung

Aktuelle News zu

03:21 UhrGehaltsinflation großes Thema für Großbanken: JPMorgan-Chef mit klarer Ansage an "Heulsusen"
03:15 UhrFixed Asset Management Software Market - 34% of Growth to Originate from North America| Evolving Opportunities with AccuFund Inc. & Acumatica Inc. |17000+ Technavio Reports
03:11 UhrNetflix-Manager & Co.: FinTech Bitpanda holt sich Experten an Bord
03:00 UhrATA Names 22 Professional Drivers as Newest America's Road Team Captains
03:00 UhrKroll Appoints David Lewis, Former Executive Secretary of the FATF, as a Managing Director to Lead its AML Advisory Practice
03:00 UhrNCH Taiwan Donated Disinfectants and Accompanied the Elders
03:00 UhrBald Eagle Announces Resignation of Board Member
02:50 UhrFood Recall Warning - Mahruse brand Halva with Black Seeds recalled due to Salmonella
02:41 UhrManulife Asia Care Survey: Hong Kong public keen to learn more about "Long COVID" as pandemic continues
02:30 UhrStretch and Shrink Film Market - 48% of the Growth to Originate from APAC |Food & Beverages Segment to be Significant for Revenue Generation |17000+ Technavio Reports
02:30 UhrCIMB Bank Philippines Collaborates with Zoloz to Strengthen Its Digital Banking Services with Advanced eKYC Solution
02:21 UhrMasterClass Announces Award-Winning HBO Veteran Len Amato as Chief Content Officer
02:10 UhrPomerantz Law Firm Notifies Investors of eHealth, Inc. of a Pending Lawsuit and Lead Plaintiff Deadline of March 18, 2022
02:06 UhrCovanta Announces Early Results of Tender Offer and Consent Solicitation for 6.000% Senior Notes due 2027
02:00 UhrHydrocephalus Market to Reach $10.17 Billion, Globally, by 2030 at 4.0% CAGR: Allied Market Research
02:00 UhrHydrocephalus Market to Reach $10.17 Billion, Globally, by 2030 at 4.0% CAGR: Allied Market Research
02:00 UhrAsia adapts to COVID-19 norm, but health and financial concerns linger
02:00 UhrSensormatic Solutions by Johnson Controls prioritizes responsible retail by continued focus and investment into sustainability practices
02:00 UhrXtalPi Partners with Excelra for GOSTAR to Enhance its Intelligent Digital Drug Discovery and Development platform
02:00 UhrFUSANG WINS REGULATORY APPROVAL FOR LANDMARK IPO OF EQUITY TOKENS
02:00 UhrDow introduces innovative technologies and sustainable solutions at Automotive World 2022
02:00 UhrRackspace Technology to Acquire Just Analytics, a Leading Provider of Cloud-based Data, Analytics, and Artificial Intelligence Services
01:56 UhrCOLUMBIA BANK BOLSTERS SEATTLE COMMERCIAL LENDING TEAM WITH FIVE NEW HIRES
01:56 UhrPeakstone Advises AutoAccessoriesGarage.com on Sale to Genuine Parts Company
01:49 UhrChina's first privately-owned high-speed railway begins operation between Hangzhou and Taizhou
01:44 UhrHyundai driving hydrogen forward with new vehicle refueller
01:30 UhrImmVira's MVR-T3011 IV completed first 2 cohorts dose-escalation of U.S. Phase I clinical study with favorable safety data
01:28 UhrTransplant Connect to Expand Human Biologics Management Software with Investment from InVita Healthcare Technologies
01:22 UhrTransplant Connect to Expand Human Biologics Management Software with Investment from InVita Healthcare Technologies
01:15 UhrDEL TACO INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Del Taco Restaurants, Inc. - TACO
01:13 UhrRUBELLITE ENERGY INC. ANNOUNCES ACHIEVEMENT OF FOURTH QUARTER PRODUCTION GUIDANCE AND SUCCESSFUL LAND PURCHASES AND PROVIDES OPERATIONAL UPDATE
01:05 UhrCStone announces the GEMSTONE-302 study of sugemalimab met the endpoint of overall survival in the first-line treatment of metastatic non-small cell lung cancer patients
01:05 UhrCStone announces the GEMSTONE-302 study of sugemalimab met the endpoint of overall survival in the first-line treatment of metastatic non-small cell lung cancer patients
01:04 UhrRoyal Bank of Canada announces NVCC subordinated debenture issue
01:02 UhrTransplant Connect to Expand Human Biologics Management Software with Investment from InVita Healthcare Technologies
01:02 UhrTransplant Connect to Expand Human Biologics Management Software with Investment from InVita Healthcare Technologies
01:01 UhrAnDAPT Introduces Power Solutions for Microchip PolarFire FPGAs
01:01 UhrPlastic Drawdown tool to help Maldives slash plastic waste by 85 percent, study reveals
01:01 UhrAnDAPT Introduces Power Solutions for Microchip PolarFire FPGAs
01:00 Uhrthyssenkrupp: Chefin Merz pumpt frische Fantasie in die Industrie-Aktie
01:00 UhrRockwell Automation Wins "Industrial IoT Solution of the Year" Award in 6th Annual IoT Breakthrough Awards Program
01:00 UhrLynk Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Study of LNK01001 in Patients with Ankylosing Spondylitis
00:54 UhrCapewell Names Lt Gen (Rtd) Edward Davis Strategic Director in the UK
00:47 UhrBrown Gibbons Lang & Company Promotes Three to Managing Director
00:40 UhrSerie-A-Runde über 15 Mio. USD: Dermaliq Therapeutics unterzeichnet Finanzierungsrunde für klinische Studien dreier transformativer Arzneimitteltherapien
00:33 UhrCapewell Names Lt Gen (Rtd) Edward Davis Strategic Director in the UK
00:30 UhrFIRST SUBJECT ENROLLED IN PHASE II/III STUDY OF EISAI'S ANTI-MTBR TAU ANTIBODY E2814 FOR DOMINANTLY INHERITED ALZHEIMER'S DISEASE (DIAD), CONDUCTED BY DIAN-TU
00:26 UhrDutch Founders legt 62 Mio. € Startkapital auf, um Gründer beim Aufbau der nächsten Welle von Marktplätzen in Europa zu unterstützen
00:24 UhrGKN Powder Metallurgy ernennt Diego Laurent zum Vorstandsvorsitzenden
00:22 UhrVONAGE INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Vonage Holdings Corp. - VG
finanzen.net zero
finanzen.net zero

Oskar

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln